Capricor Therapeutics, Inc. (NASDAQ:CAPR) Given Consensus Rating of "Buy" by Analysts

Key Points

• Capricor Therapeutics, Inc. (NASDAQ:CAPR) has received a consensus recommendation of "Buy" from nine research firms, with an average one-year price target of $22.56.
• Institutional investors have significantly increased their stakes in Capricor, with Bank of America Corp DE raising its holdings by 938.9% in the last quarter.
• The company recently reported a loss of ($0.57) EPS for the last quarter, missing the consensus estimate and highlighting ongoing financial challenges.

Shares of Capricor Therapeutics, Inc. (NASDAQ:CAPR - Get Free Report) have been given a consensus rating of "Buy" by the nine brokerages that are currently covering the firm, Marketbeat Ratings reports. Eight investment analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $22.5556.

A number of brokerages recently issued reports on CAPR. Jones Trading lowered their price target on shares of Capricor Therapeutics from $40.00 to $29.00 and set a "buy" rating for the company in a research report on Wednesday, June 25th. Wall Street Zen cut shares of Capricor Therapeutics from a "hold" rating to a "sell" rating in a research report on Thursday, May 22nd. Alliance Global Partners reissued a "buy" rating on shares of Capricor Therapeutics in a research report on Monday, July 14th. HC Wainwright lowered their price target on shares of Capricor Therapeutics from $77.00 to $24.00 and set a "buy" rating for the company in a research report on Friday, July 11th. Finally, Cantor Fitzgerald reissued an "overweight" rating and set a $30.00 price target on shares of Capricor Therapeutics in a research report on Wednesday, May 14th.

Capricor Therapeutics Price Performance

Capricor Therapeutics stock traded down $0.05 during trading hours on Tuesday, reaching $6.28. The stock had a trading volume of 839,694 shares, compared to its average volume of 1,336,131. The stock has a market cap of $287.12 million, a PE ratio of -3.83 and a beta of 0.73. Capricor Therapeutics has a 52 week low of $3.98 and a 52 week high of $23.40. The company has a fifty day simple moving average of $7.92 and a 200-day simple moving average of $10.27.

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last announced its earnings results on Monday, August 11th. The biotechnology company reported ($0.57) earnings per share for the quarter, missing analysts' consensus estimates of ($0.48) by ($0.09). Capricor Therapeutics had a negative net margin of 181.71% and a negative return on equity of 62.71%. Research analysts predict that Capricor Therapeutics will post -1.21 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Nuveen Asset Management LLC raised its holdings in Capricor Therapeutics by 392.7% in the fourth quarter. Nuveen Asset Management LLC now owns 169,111 shares of the biotechnology company's stock worth $2,334,000 after buying an additional 134,791 shares during the last quarter. The Manufacturers Life Insurance Company raised its holdings in shares of Capricor Therapeutics by 22.4% during the fourth quarter. The Manufacturers Life Insurance Company now owns 12,919 shares of the biotechnology company's stock valued at $178,000 after purchasing an additional 2,361 shares during the last quarter. Two Sigma Investments LP raised its holdings in shares of Capricor Therapeutics by 223.6% during the fourth quarter. Two Sigma Investments LP now owns 119,047 shares of the biotechnology company's stock valued at $1,643,000 after purchasing an additional 82,254 shares during the last quarter. Voya Investment Management LLC purchased a new position in shares of Capricor Therapeutics during the fourth quarter valued at approximately $150,000. Finally, Bank of America Corp DE raised its holdings in shares of Capricor Therapeutics by 938.9% during the fourth quarter. Bank of America Corp DE now owns 170,543 shares of the biotechnology company's stock valued at $2,353,000 after purchasing an additional 154,127 shares during the last quarter. 21.68% of the stock is owned by hedge funds and other institutional investors.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.